Aardvark Therapeutics, Inc. AARD R2KPHARMA
Company Overview
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -108.2%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -108.20% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -87.59% |
| 6 Months: | -74.21% |
| 3 Months: | -79.22% |
| 1 Month: | -74.95% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)20.32 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -108.2% CAGR over 5 years.
- Trading 92.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 20 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AARD Aardvark Therapeutics, Inc. R2KPHARMA | 1.39 | -0.45 | $30.42M | 0.00% | -58.82% | -66.02% | - | -108.20% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 10.47M | 15.85M | 17.70M | 18.70M | 22.46M |
| Operating Income | -2.17M | -6.07M | - | - | -10.47M | -15.85M | -17.70M | -18.70M | -22.46M |
| EBITDA | - | - | - | - | -10.46M | -15.84M | -17.69M | -18.69M | -22.45M |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | -9.31M | -14.37M | -16.32M | -17.60M | -21.59M |
| Tax Provision | - | - | - | - | - | - | - | - | - |
| Net Income | -2.18M | -5.45M | - | - | -9.31M | -14.37M | -16.32M | -17.60M | -21.59M |
| Diluted EPS | -0.55 | -1.37 | - | - | -0.71 | -0.66 | -0.75 | -0.81 | -0.99 |
| R&D Expense | 1.21M | 4.03M | 4.07M | - | 7.75M | 13.14M | 13.74M | - | 16.57M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 10.87M | 6.65M | 22.67M | 62.73M |
| Operating Income | -10.87M | -6.65M | -22.67M | -62.73M |
| EBITDA | -10.76M | -6.65M | -22.65M | -62.69M |
| Interest Expense | - | - | - | - |
| Pretax Income | -13.56M | -7.21M | -20.59M | -57.59M |
| Tax Provision | - | - | - | - |
| Net Income | -13.56M | -7.21M | -20.59M | -57.59M |
| Diluted EPS | -1.39 | -0.56 | -0.96 | -2.93 |
| R&D Expense | - | - | 17.36M | 48.94M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 16.76M | 10.54M | 77.51M | 117.18M |
| Current Assets | 16.49M | 10.37M | 74.14M | 111.89M |
| Cash & Equivalents | 15.56M | 9.73M | 61.64M | 47.05M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 44.68M | 45.34M | 132.15M | 10.55M |
| Current Liabilities | 595.00K | 1.38M | 4.93M | 10.55M |
| Long Term Debt | - | - | - | - |
| Total Debt | 262.00K | 162.00K | 779.00K | 441.00K |
| Total Equity | -27.92M | -34.80M | -54.64M | 106.63M |
| Shares Outstanding | 21.38M | 21.38M | 21.69M | 21.82M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -10.54M | -5.82M | -18.09M | -54.17M |
| Investing Cash Flow | -1.00M | 0 | -12.00M | -49.67M |
| Financing Cash Flow | 225.00K | 0 | 81.99M | 89.25M |
| Capital Expenditure | - | - | -109.00K | -95.00K |
| Free Cash Flow | -10.54M | -5.82M | -18.20M | -54.27M |
| Net Change in Cash | -11.32M | -5.82M | 51.91M | -14.59M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 48.6% | 20.7% | 37.7% | -54.0% |
| ROCE % | -67.3% | -72.7% | -31.2% | -58.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Decheng Capital LLC | 17.90% | 3.92M | $18.65M |
| 2 | Citadel Advisors Llc | 5.86% | 1.28M | $6.11M |
| 3 | Laurion Capital Management, LP | 4.73% | 1.03M | $4.92M |
| 4 | Vanguard Capital Management LLC | 2.57% | 562.88K | $2.68M |
| 5 | AQR Capital Management, LLC | 2.19% | 480.25K | $2.29M |
| 6 | EcoR1 Capital, LLC | 1.81% | 396.19K | $1.89M |
| 7 | Adage Capital Partners GP L.L.C. | 1.37% | 300.00K | $1.43M |
| 8 | Blackrock Inc. | 0.85% | 187.04K | $890.33K |
| 9 | Geode Capital Management, LLC | 0.68% | 149.84K | $713.26K |
| 10 | Cantor Fitzgerald, L.P. | 0.53% | 116.58K | $554.93K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AARD
Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
HERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratoryHQ-CT scores fell by Week 2 of dose escalation on ARD-101 and returned to near baseline within two weeks of stopping treatme…
Aardvark Therapeutics stock surges as FDA lifts clinical hold
Investing.com -- Aardvark Therapeutics Inc (NASDAQ:AARD) shares jumped 21% in after-hours trading Thursday after the FDA lifted the clinical hold on the company's ARD-101 drug candidate for the treatment of hyperphagia in Prader-Willi Syndr…
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume Aardvark will host a webcast to review available dataset from the terminated Phase 3 HERO trial and OLE trial on Friday, October 23, 2026, at 8:00 a.m…
All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy
Aardvark Therapeutics, Inc. (AARD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Prader-Willi Syndrome Market to Expand by 2036 as New Therapeutic Opportunities Address Unmet Clinical Needs | DelveInsight
Recently published Prader-Willi Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Prader-Willi syndrome emerging drugs, market share of individual therapies, and current and forecasted ma…
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
Brings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions from Abivax, Alumis, MyoKardia and Genentech/Roche SAN DIEGO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or …
AARD — Frequently Asked Questions
What is the current share price of Aardvark Therapeutics, Inc. (AARD)?
As of 2026-10-23 16:27 PDT, Aardvark Therapeutics, Inc. (AARD) trades at $1.39 on NasdaqGS. Its 52-week range is $1.39 to $17.41.
What is the market capitalisation of AARD?
Aardvark Therapeutics, Inc. (AARD) has a market capitalisation of $30.42M on NasdaqGS.
What is the P/E ratio of AARD?
AARD trades at a trailing price-to-earnings (P/E) ratio of -0.45. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.39.
What is the return on equity (ROE) of AARD?
AARD has a return on equity (ROE) of -66.02%. Its return on capital employed (ROCE) is -58.82%.
Is AARD a good stock to buy?
This page provides a data-driven analysis of Aardvark Therapeutics, Inc. (AARD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.